Get the Stockscreener App
2.86
2.05%
-0.06
After Hours:
2.86
Pyxis Oncology Inc stock is traded at $2.86, with a volume of 609.44K.
It is down -2.05% in the last 24 hours and down -6.54% over the past month.
Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.
See More
Previous Close:
$2.92
Open:
$2.91
24h Volume:
609.44K
Relative Volume:
0.47
Market Cap:
$238.55M
Revenue:
$13.86M
Net Income/Loss:
$-81.74M
P/E Ratio:
-2.1939
EPS:
-1.3036
Net Cash Flow:
$-66.98M
1W Performance:
-14.11%
1M Performance:
-6.54%
6M Performance:
+100.00%
1Y Performance:
+38.83%
1-Day Range:
$2.785
$2.92
1-Week Range:
$2.785
$3.405
52-Week Range:
$1.03
$5.55
Pyxis Oncology Inc Stock (PYXS) Company Profile
Name
Pyxis Oncology Inc
Sector
Industry
Phone
(617) 221-9059
Address
321 HARRISON AVENUE, BOSTON
Compare PYXS vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PYXS
Pyxis Oncology Inc
|
2.86 | 238.55M | 13.86M | -81.74M | -66.98M | -1.3036 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Pyxis Oncology Inc Stock (PYXS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-03-25 | Resumed | Stifel | Buy |
| Sep-04-25 | Initiated | Guggenheim | Buy |
| Nov-21-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Nov-08-24 | Initiated | Stephens | Overweight |
| Aug-08-24 | Initiated | Stifel | Buy |
| May-07-24 | Resumed | Jefferies | Buy |
| Feb-09-24 | Initiated | BTIG Research | Buy |
| Jan-23-24 | Initiated | Leerink Partners | Outperform |
| Sep-05-23 | Initiated | RBC Capital Mkts | Outperform |
| Nov-02-21 | Initiated | BofA Securities | Neutral |
| Nov-02-21 | Initiated | Credit Suisse | Outperform |
| Nov-02-21 | Initiated | Jefferies | Buy |
View All
Pyxis Oncology Inc Stock (PYXS) Latest News
LifeSci Capital Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Pyxis Oncology stock falls 3.73 percent after trial update - AD HOC NEWS
Pyxis Oncology Inc (PYXS) Key Financial Ratios – Valuation, Profitability & More - Value Research
Pyxis Oncology, Inc.(NasdaqGS: PYXS) added to S&P Global BMI Index - marketscreener.com
Pyxis Oncology Inc (NASDAQ: PYXS) Share Price, PYXS Stock News, PYXS Share Price & Updates - kalkine.com.au
Pyxis Oncology: Setbacks Costing Nearly 2 Years Of Recovery (NASDAQ:PYXS) - Seeking Alpha
PYXIS ONCOLOGY, INC. : WELLS FARGO RAISES TARGET PRICE TO $19 FROM $12 - webull.com
Wells Fargo raises Pyxis Oncology stock price target on MICVO data By Investing.com - Investing.com South Africa
Wedbush raises Pyxis Oncology stock price target on trial data By Investing.com - Investing.com South Africa
Enterprise value to revenue forward of Pyxis Oncology, Inc. – NASDAQ:PYXS - TradingView
Pyxis Oncology stock price target raised to $8 by H.C. Wainwright By Investing.com - Investing.com Australia
Pyxis Oncology Stock Soars Over 5% Overnight: Here's What You Need to Know - webull.com
Pyxis Oncology (NASDAQ: PYXS) to Launch Phase 3 Trial for MICVO in Mid-2027 Following Promising Phase 1 Results - Kalkine Media
Pyxis Oncology stock price target raised to $8 by H.C. Wainwright - Investing.com Nigeria
A Quick Look at Today's Ratings for Pyxis Oncology(PYXS.US), With a Forecast Between $6 to $19 - Moomoo
Wells Fargo raises Pyxis Oncology stock price target on MICVO data - Investing.com Australia
Wedbush raises Pyxis Oncology stock price target on trial data - Investing.com India
Pyxis Oncology, Inc. (PYXS) Discusses MICVO Monotherapy Phase I Clinical Data in Head and Neck Squamous Cell CarcinomaSlideshow (NASDAQ:PYXS) 2026-09-10 - Seeking Alpha
Pyxis Oncology Slides 7% as Analysts Flag Toxicity Concerns for Lead Cancer Drug - finance.biggo.com
Pyxis Oncology Analyst Flags Key Safety Liabilities from Cancer Drug - Benzinga
Wedbush Lifts Price Target on Pyxis Oncology to $8 From $6, Keeps Outperform Rating - marketscreener.com
Pyxis Oncology shares fall 7% despite updated MICVO trial results - Yahoo Finance
PYXS: MICVO showed strong efficacy and manageable safety in advanced head and neck cancer patients - TradingView
Pyxis Oncology stock falls 7% despite positive trial data By Investing.com - Investing.com Canada
Pyxis slides after new early-stage trial data for lead asset in head and neck cancer - TradingView
Pyxis Oncology Reports 36% Response Rate in Phase 1 MICVO Study - marketscreener.com
Pyxis Oncology Reports Promising MICVO Phase 1 Results - TipRanks
Pyxis Oncology reports 36% cORR, 6.2‑month mPFS and 79% 12‑month OS probability for MICVO in 2L+ HNSCC - TradingView
Head and neck cancer drug from Pyxis Oncology (PYXS) shows tumor responses ahead of 500-patient trial - stocktitan.net
A cancer treatment showed disease control in 94% of trial patients. Pyxis plans a roughly 500-patient trial. - stocktitan.net
PYXS: MICVO achieved rapid, deep responses and strong disease control in advanced head and neck cancer - TradingView
Pyxis Oncology Announces Positive Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC) - marketscreener.com
symbol__ Stock Quote Price and Forecast - CNN
Pyxis Oncology Shares Gain 9.25% After HoursPyxis Oncology (NASDAQ:PYXS) - Benzinga
Pyxis Oncology to present clinical data on cancer therapy By Investing.com - Investing.com South Africa
Pyxis Oncology to present clinical data on cancer therapy - investing.com
Updated cancer-drug data will be presented Sept. 9. A Memorial Sloan Kettering expert will join Pyxis Oncology. - Stock Titan
Pyxis Oncology Names Thomas Civik CEO and Chairman Ahead of MICVO Milestones - citybiz
Pyxis Oncology Appoints Thomas Civik as CEO and Chairman of the Board - Oncodaily
Pyxis Oncology Names Thomas Civik CEO, Board Chairman - marketscreener.com
Pyxis Oncology names Thomas Civik as permanent CEO and chairman By Investing.com - Investing.com Nigeria
Pyxis Oncology, Inc. Announces Board Changes - marketscreener.com
Pyxis Oncology, Inc. Announces Appointment of Thomas Civik to Chief Executive Officer, Effective September 4, 2026 - marketscreener.com
Pyxis Oncology Elevates Thomas Civik to Permanent CEO - TipRanks
Pyxis Oncology names Thomas Civik as permanent CEO and chairman - Investing.com India
Pyxis Oncology Appoints Thomas Civik Chief Executive Officer and Chairman of the Board - manilatimes.net
Pyxis Oncology (PYXS) CEO receives 2.5M options at $3.89 - Stock Titan
Pyxis Oncology Inc Stock (PYXS) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):